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Abstract: Portal vein ligation (PVL) induces liver growth prior to resection. Associating liver parti-
tion and portal vein ligation (PVL plus transection=ALPPS) or the addition of the prolyl-hydroxylase
inhibitor dimethyloxalylglycine (DMOG) to PVL both accelerate growth via stabilization of HIF-฀ sub-
units. This study aims at clarifying the crosstalk of hepatocytes (HC), hepatic stellate cells (HSC) and
liver sinusoidal endothelial cells (LSEC) in accelerated liver growth. In vivo, liver volume, HC prolifer-
ation, vascular density and HSC activation were assessed in PVL, ALPPS, PVL+DMOG and DMOG
alone. Proliferation of HC, HSC and LSEC was determined under DMOG in vitro. Conditioned media
experiments of DMOG-exposed cells were performed. ALPPS and PVL+DMOG accelerated liver growth
and HC proliferation in comparison to PVL. DMOG alone did not induce HC proliferation, but led to
increased vascular density, which was also observed in ALPPS and PVL+DMOG. Activated HSC were
detected in ALPPS, PVL+DMOG and DMOG, again not in PVL. In vitro, DMOG had no proliferative
effect on HC, but conditioned supernatant of DMOG-treated HSC induced VEGF-dependent prolifer-
ation of LSEC. Transcriptome analysis confirmed activation of proangiogenic factors in hypoxic HSC.
Hypoxia signaling in HSC induces VEGF-dependent angiogenesis. HSC play a crucial role in the cellular
crosstalk of rapid liver regeneration.
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Hypoxia sensing by hepatic stellate 
cells leads to VEGF-dependent 
angiogenesis and may contribute to 
accelerated liver regeneration
Konstantin Dirscherl  1,2, Martin Schläpfer1,2, Birgit Roth Z’graggen1,2, Roland H Wenger1, 
Christa Booy1,2, Renata Flury-Frei3, Rita Fatzer3, Costica Aloman4, Birke Bartosch5, 
Romain Parent6, Vartan Kurtcuoglu  1, Diane de Zélicourt1, Donat R. Spahn2, Beatrice Beck 
Schimmer1,2,9 & Erik Schadde1,7,8*
Portal vein ligation (PVL) induces liver growth prior to resection. Associating liver partition and 
portal vein ligation (PVL plus transection=ALPPS) or the addition of the prolyl-hydroxylase inhibitor 
dimethyloxalylglycine (DMOG) to PVL both accelerate growth via stabilization of HIF-α subunits. 
This study aims at clarifying the crosstalk of hepatocytes (HC), hepatic stellate cells (HSC) and liver 
sinusoidal endothelial cells (LSEC) in accelerated liver growth. In vivo, liver volume, HC proliferation, 
vascular density and HSC activation were assessed in PVL, ALPPS, PVL+DMOG and DMOG alone. 
Proliferation of HC, HSC and LSEC was determined under DMOG in vitro. Conditioned media 
experiments of DMOG-exposed cells were performed. ALPPS and PVL+DMOG accelerated liver growth 
and HC proliferation in comparison to PVL. DMOG alone did not induce HC proliferation, but led to 
increased vascular density, which was also observed in ALPPS and PVL+DMOG. Activated HSC were 
detected in ALPPS, PVL+DMOG and DMOG, again not in PVL. In vitro, DMOG had no proliferative 
effect on HC, but conditioned supernatant of DMOG-treated HSC induced VEGF-dependent 
proliferation of LSEC. Transcriptome analysis confirmed activation of proangiogenic factors in hypoxic 
HSC. Hypoxia signaling in HSC induces VEGF-dependent angiogenesis. HSC play a crucial role in the 
cellular crosstalk of rapid liver regeneration.
The liver proliferates after rerouting portal vein blood flow without removal of liver mass, likely because portal 
vein blood contains trophic factors1,2 to maintain hepatocyte number and function3. Portal vein blood rerouting 
is used by surgeons to induce liver growth prior to liver resection in cases of small prospective (future) liver rem-
nants (FLR) since 19864–6. Portal vein branch embolization (PVE) of the hemi-liver with or without segment 4 
is performed by interventional radiologists7 to increase volume by about 38% of the total liver volume within 4 
to 6 weeks6. Portal vein ligation (PVL) by surgeons induces similar volume growth like PVE. However, volume 
increase with PVE or PVL is remarkably slow8. Recently, Associating Liver Partition and Portal vein ligation for 
Staged hepatectomy (ALPPS) was introduced as a surgical procedure in two stages, which combines PVL with 
parenchymal transection in a first stage, followed by hepatectomy in a second stage after only 7–10 days9,10. In 
animals models, ALPPS has been shown to increase portal venous blood flow per unit tissue just like PVL, but 
unlike PVL, the formation of portal collaterals over time is abrogated because of the parenchymal transection11. 
The consequence is persistent high portal flow in the small growing liver12. This high portal flow after ALPPS 
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induces a persistent hypoxic environment with high levels of hypoxia-inducible factor 1α (HIF-1α) in the grow-
ing liver, whereas hypoxia does not persist in PVL13, likely due to the development of collaterals that decompress 
the portal hyperflow. It has been demonstrated that HIFα subunit stabilizers such as prolyl-hydroxylase inhibitors 
(PHI) like DMOG, which induce hypoxia signaling, also accelerate liver regeneration in rodents, and that factors 
increasing tissue oxygenation abrogate this effect13,14. It is also known that regeneration after partial resection is 
accelerated in mice genetically deficient for prolyl-hydroxylases15,16, which supports the role of hypoxia to accel-
erate liver regeneration.
Hypoxia signaling in the regenerating liver accelerates liver regeneration, but it is unclear which cell type 
(hepatocytes or non-parenchymal cells) transduces oxygen sensing into a proliferative signal in ALPPS. It is also 
not known what a short-term treatment of the normal liver with HIFα-stabilizing drugs does without portal vein 
rerouting. Current literature only provides information that genetic defects of von Hippel-Lindau syndrome and 
prolyl-hydroxylases - knockout mice with long term stabilization of HIFα subunits in the liver - lead to vascular 
malformations and liver steatosis17.
In this study, the effect of HIFα subunit stabilization using DMOG on the liver was investigated in vivo in rat 
models of PVL, ALPPS, PVL+ DMOG, DMOG-treatment of normal liver without portal vein rerouting. Volume 
changes and changes in histology were investigated. Additionally, isolated interrogation of the cellular compo-
nents of the liver was performed using immortalized cell lines of hepatocytes (HC), hepatic stellate cells (HSC) 
and liver sinusoidal endothelial cells (LSEC) as well as primary cell isolates of HSC (pHSC) and LSEC (pLSEC) to 
better understand which cell types of the liver are involved in hypoxia sensing and how they affect acceleration of 
hepatocyte proliferation. Based on previous reports18,19, we hypothesized that HSC play a crucial role in hypoxia 
sensing and cellular crosstalk.
Results
Animal models. The right middle lobe (RML, 25% of the total liver volume) was used as FLR in models of 
PVL and ALPPS with 25% future liver remnant which have been established in this laboratory and were previ-
ously described Fig. 1A-C13,20. Control animals for PVL+DMOG, the prolyl-hydroxylase inhibitor dimethylox-
alylglycine (DMOG) was injected intraperitoneally 12 h prior to PVL (Fig. 1D). For treatment of normal rat livers 
(Fig. 1E), DMOG was injected intraperitoneally and the injection was repeated after 24 and 48 h (phosphate-buff-
ered saline, PBS, as control).
ALPPS and PVL+DMOG increase liver volume and proliferation. A total of n = 25 surgeries were performed in 
rats, n = 5 in each group (control, PVL, ALPPS, VPL+DMOG, DMOG alone). One animal died within 24 h after 
PVL, one animal died intraoperatively in the ALPPS group due to bleeding during hilar dissection and injury to 
the hepatic artery and one in the PVL+DMOG group within 24 h due to intraoperative hematoma resulting in a 
perioperative mortality rate of 12% (n = 3/25 for all animals). Portal re-routing with PVL induced a 2 cc increase 
in the RML volume by CT volumetry after 72 h. ALPPS as well as PVL+DMOG led to a 3.6 and 3.4 cc volume 
increase within 72 h. DMOG alone led to no increase in volume in the exemplarily selected RML of the rat liver 
(Fig. 1F). Hepatocyte proliferation in ALPPS and PVL+DMOG was demonstrated by an increased number of 
Ki-67 positive nuclei, while PVL and DMOG alone did not affect hepatocyte proliferation rate at 72 h (Fig. 1G).
Hypoxia and hypoxia signaling in liver cells in culture reduce cell proliferation. Incubation of HC, HSC and LSEC 
with DMOG in vitro reduced rather than enhanced proliferation of all three cell lines (n = 3 passages for each 
group, p < 0.001) (Fig. 2A-C). Similarly, exposure of HC, HSC and LSEC to hypoxic cell culture conditions 
resulted in a decreased cell proliferation (n = 3 passages for each group, p < 0.01) (Fig. 2D-F). To exclude toxicity 
of DMOG, HC, HSC and LSEC cells were incubated with 1 mM DMOG for 72 h and caspase 3 activity was meas-
ured as marker for apoptosis (Fig. 2G). In the presence of DMOG, caspase 3 activity was significantly reduced 
(n = 3 passages, p < 0.001), suggesting that increased apoptosis does not account for the decreased proliferation 
rate.
Conditioned media from hypoxic HSC induce LSEC proliferation. Since there was no pro-proliferative effect 
of hypoxia or DMOG on HC and non-parenchymal cells in cell culture, cellular crosstalk was examined using 
conditioned media. In a first approach, HC were incubated with either medium from DMOG-treated HSC or 
LSEC. As shown in Fig. 3A,B, the conditioned media of DMOG-treated HSC and LSEC impaired growth of HC 
(n = 3 passages for each group, p < 0.05). Then, HSC were incubated with medium from DMOG-treated LSEC. 
There was an increase of HSC proliferation with medium from DMOG-exposed LSEC (n = 3 passages, p < 0.05) 
(Fig. 3C). Also, medium from DMOG-treated HCS significantly accelerated proliferation of LSEC (n = 3 pas-
sages, p < 0.05) (Fig. 3D).
Confirmation of acceleration of LSEC proliferation by conditioned media form DMOG-exposed 
HSC in primary cell culture (pLSEC, pHSC). Immortalized cells lines may react differently from cells after 
primary isolation from the liver. The findings of screening for the effect of conditioned media of DMOG-treated 
HSC on LSEC proliferation was therefore validated in vitro in pHSC and the pLSEC. Results are shown in Fig. 3E, 
where similarly to Fig. 3D DMOG-treated pHSC supernatants accelerated proliferation of pLSEC (n = 3 passages, 
p < 0.001).
Transcriptome analysis of DMOG-treated HSC and conditioned LSEC revealed increased angiogenesis path-
ways. For a more detailed understanding of the interaction and the signaling between HSC and LSEC, tran-
scriptome analysis was performed of DMOG-treated HSC. Furthermore, LSEC, incubated with the conditioned 
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media of DMOG-treated HSC, were analyzed. The transcriptome data from this study are uploaded in the GEO 
data repository under the following accession number: Series record GSE131168. In DMOG-treated HSC, 2261 
genes were differentially expressed, 759 transcripts were up-regulated and 1502 down-regulated with a fold 
change of 2 or more. Functional annotation of the transcripts was performed using DAVID21,22. The cluster ‘HIF-1 
pathway’ referred to 9 up-regulated and 3 down-regulated genes, the cluster ‘angiogenesis’ to 7 up-regulated 
and 12 down-regulated genes, the cluster vascular growth factor ‘VEGF pathway’ to 4 up-regulated and 2 
down-regulated genes, the cluster ‘apoptosis’ to 33 up-regulated and 40 down-regulated genes, and the cluster 
Figure 1. Rat models of regenerative liver surgery, volumetry and proliferation of rat livers after 72 h. (A) Rat 
liver anatomy with the right lobe (RL), the right and left middle lobe (RML, LML), the left lateral lobe (LLL), 
and the caudate lobe (CL). (B) Rat model of portal vein ligation (PVL): ligation of RL, LLL + LML, and CL. 
The dark liver area denotes the deportalized part of the rat liver with only arterial blood supply, the light browns 
one the liver with portal and arterial bi-perfusion. (C) Rat model of Associating Liver Partition and Portal 
vein ligation for Staged hepatectomy (ALPPS): transection of the ML along the ischemic line between RML 
and LML in addition to PVL. (D) Rat model of PVL+DMOG: i.p. administration of 200 µg/g body weight of 
dimethyloxalylglycine (DMOG) 12 h before PVL. (E) Rat model of DMOG application to liver: Repetitive (3x, 
up to 48 h) intraperitoneal (i.p.) application of DMOG without any rerouting of portal vein blood. (F) Growth 
assessment by volumetry using a small animal CT scanner after giving i.v. contrast to the animal directly 
after intervention and after 72 h to assess regeneration of the right middle lobe. Volume change is expressed 
as volume difference after 72 h in cubic centimeters after PVL, ALPPS, PVL+DMOG, DMOG alone and and 
normal liver control after intraperitoneal phosphate-buffered saline (control) application. (G) Proliferation 
assessment by histology. Ki-67 staining of the RML 72 h after PVL, ALPPS, PVL+DMOG, DMOG alone and 
normal liver control after intraperitoneal phosphate-buffered saline (control) application. n = 5 animals for 
controls and DMOG alone, n = 4 for ALPPS, PVL and PVL+DMOG. ***p < 0.001.
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‘p53 pathway’ revealed 6 up-regulated and 4 down-regulated genes (Supplementary Table 1). In LSEC, incubated 
with conditioned medium from DMOG-treated HSC, 270 genes were differentially expressed, of which 129 were 
up- and 141 down-regulated. The ‘HIF-1 pathway’ cluster referred here to 6 up-regulated genes, the cluster ‘angi-
ogenesis’ also to 6 upregulated genes, 24 up-regulated and 18 down-regulated genes were functionally linked to 
apoptosis (Supplementary Table 2).
Hypoxic HSC produce VEGF and stimulate LSEC proliferation. The finding that VEGF and angiogenesis path-
ways were strongly represented at the transcriptome level led to the measurement of VEGF in conditioned media 
of DMOG-treated HSC. VEGF concentration doubled in conditioned medium of DMOG-treated HSC (329 pg/
ml vs 607 pg/ml, p < 0.01) (Fig. 3F).
To evaluate the relevance of VEGF to induce LSEC proliferation, VEGF protein depletion was performed in 
medium from DMOG-treated or control HSC, which was confirmed by ELISA (Fig. 3F). When exposing HSC 
with VEGF-depleted medium from DMOG-exposed HSC, proliferation was strongly reduced, but LSEC still 
proliferated significantly more in media of DMOG-treated HSC than in media of non-treated HSC (p < 0.001), 
suggesting that other (angiogenetic) factors are present in the supernatant of DMOG treated HSC. The much 
lower proliferation level after VEGF depletion however shows that VEGF is the main growth factor to support 
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Figure 2. Effect of hypoxic signaling and hypoxia on liver cells in vitro. The iCELLigence system measures cell 
proliferation by impedance and thereby assesses proliferation of about 4500 plated cells over a time continuum. 
Bold lines represent mean values of the individual measurements, shadowed lines represent the SD of individual 
measurements. (A) Hepatocytes (HC) proliferation over 72 h after incubation with 1 mM dimethyloxalylglycine 
(DMOG) (B) Hepatic stellate cells (HSC) proliferation over 72 h after incubation with 1 mM DMOG and (C) 
Liver sinusoidal endothelial cells (LSEC) proliferation over 72 h after incubation with 1 mM DMOG. Control 
cells were exposed to phosphate-buffered saline instead of DMOG. (D, E, F) Proliferation of the 3 respective 
types were also cultivated in hypoxic conditions of 2% O, and proliferation was measured over 72 h. (G) 
HC, HSC, and LSEC were incubated with 1 mM DMOG for 72 h and caspase 3 activity was measured and 
normalized to the DNA content. A-F: n = 3 independent experiments (cell passages with two measurements) 
were performed for each group A-F and representative graphic outputs for each experiment are shown here:  
**p < 0.01; ***p < 0.001.
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Figure 3. Effect of hypoxia-conditioned media on hepatocytes, hepatic stellate and endothelial cells in vitro 
and role of VEGF. The iCELLigence system measures cell proliferation by impedance and thereby assesses 
proliferation of about 4500 plated cells over a time continuum. Bold lines represent mean values of the 
individual measurements, shadowed lines represent the SD of individual measurements. (A) Hepatocyte (HC) 
proliferation over 72 h, after exposure to conditioned medium from hepatic stellate cells (HSC), incubated with 
1 mM dimethyloxalylglycine (DMOG) for 24 h. (B) Hepatocyte (HC) proliferation over 72 h, after exposure 
to conditioned medium from Liver sinusoidal endothelial cells (LSEC) incubated with 1 mM DMOG for 
24 h. (C) Hepatic stellate cell (HSC) proliferation over 72 h, after exposure to conditioned media from LSECs, 
incubated with 1 mM DMOG for 24 h. (D) LSEC proliferation over 72 h after exposure to conditioned medium 
from HSC, incubated with 1 mM DMOG for 24 h. (E) Validation of the finding that DMOG-exposed HSC 
supernatants stimulate LSEC proliferation, using primary cell culture of HSC (pHSC) and LSEC (pLSEC). 
pLSEC proliferation over 72 h after exposure to conditioned medium from pHSC, incubated with 1 mM 
DMOG for 24 h. (F) VEGF concentration as measured by enzyme-linked immunosorbent assay (ELISA) in 
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To verify this higher VEGF presence in vivo during rapid liver regeneration, we performed immunohisto-
chemistry for VEGF following slow regeneration after 72 h PVL with moderate hypoxia, or rapid regeneration 
after ALPPS with pronounced hypoxia, as well as after PVL+DMOG and DMOG alone. Though there was no 
significant difference between DMOG application and control (47.7 vs 48.3 counts per mm2, p = 0.96), VEGF 
was moderately increased 72 h after PVL (500 counts per mm2, p < 0.0001 vs control) and highly present after 
the rapid regeneration models ALPPS (1216 counts per mm2, p < 0.0001 vs control and p = 0.0002 vs PVL) and 
PVL+DMOG (1498 counts per mm2, p < 0.0001 vs control and vs PVL; Fig. 3H). According VGEV staining in 
PVL and ALPPS is shown in Fig. 3I,J, respectively.
Liver tissue undergoing rapid hypertrophy shows hypervascularity by vWF and CD34 staining. To better understand 
a putative effect of VEGF produced by HSC with activated hypoxia signaling during rapid liver regeneration, we per-
formed immunohistochemistry for the endothelial marker von Willebrand factor (vWF) in rat livers to detect dif-
ferences in endothelial density in vivo, following slow regeneration after 72 h PVL with moderate hypoxia, or rapid 
regeneration after ALPPS with pronounced hypoxia. Quantification showed that vascular density did not change 
after 72 h in slow regeneration (PVL), but significantly increased in rapid regeneration after ALPPS as well as after 
PVL+DMOG (p < 0.001 PVL vs ALPPS or PVL+DMOG) (Fig. 4A). Vascular density after DMOG application to nor-
mal livers (Fig. 4B) with PBS; Fig. 4C with DMOG) was comparable to ALPPS and PVL+DMOG (Fig. 4A) using vWF 
staining. Of note, no volume increase or increased Ki-67 staining of HC were observed in these livers (see Fig. 1F,G).
Like vWF, CD34 is a common LSEC/endothelial cell marker in the liver during endothelial differentiation 
and was used to additionally evaluate vascularity. Both vWF and CD34 are also expressed in TRP3 cells, which 
were used for cell culture experiments in this study. CD34 staining demonstrated a significant increase in staining 
in ALPPS and PVL+ DMOG compared to PVL (p < 0.05 PVL vs ALPPS or p < 0.001 PVL vs PVL+DMOG) 
(Fig. 4D). Also, livers after PVL had increased staining compared to livers from control animals (Fig. 4E) or livers 
after the injection of DMOG alone (Fig. 4F).
Activation of HSC in vivo in ALPPS, DMOG+PVL and DMOG treated livers. Because conditioned 
media from hypoxic HSC induced LSEC proliferation in cell culture, and because DMOG-treated HSC were found 
to differentially express over 2000 genes compared to non-hypoxic HSC, HSC were interrogated for activation in 
vivo using desmin staining. Increased desmin synthesis and formation of desmin-containing intermediate filaments 
(IFs) are signs of transdifferentiation of HSC into myofibroblast-like cells. These desmin-enriched myofibroblast-like 
cells are the source of fibrotic extracellular matrix in chronically diseased liver23. We found that at 72 h after the pro-
cedures desmin was increased in the growing livers in ALPPS and PVL+DMOG compared to control livers (desmin 
signal 0.35% and 0.35% vs 0.03% total area, p < 0.001) (Fig. 4G). DMOG application in normal livers also activated 
HSC (0.14% desmin area vs 0.03%, p < 0.001) (Fig. 4H with PBS; Fig. 4I with DMOG).
We also used a second activation marker for HSC, α-smooth muscle actin (αSMA). The findings showed a 
correlation to the results of the desmin staining with an increase in ALPPS (αSMA signal 12.6% vs 0.13% total 
area, p < 0.001) and PVL+DMOG (14.2% vs 0.13% total area, p < 0.001) livers more than in PVL livers (10.1% 
vs 0.13% total area, p < 0.001) (Fig. 4J). Even DMOG application in normal livers activated HSC (0.52% vs 0.13% 
total area, p = 0.0004) (Fig. 4K with PBS; Fig. 4L with DMOG).
Possible mechanism for rapid liver regeneration. Genes referred to in the clusters ‘HIF-1 pathway’, ‘VEGF 
pathway’, ‘angiogenesis’, ‘apoptosis’, ‘p53 pathway’, ‘ECM-ECM-receptor-interaction’ by DAVID (Supplementary 
Tables 1 and 2) were further evaluated using the National Center for Biotechnology Information (NCBI) gene data-
base. Dimethyloxalylglycine treatment of HSC and incubation of LSEC with conditioned media from HSC after a 
24-hour DMOG exposure caused a complex change in the transcriptome of both HSC and LSEC that led to induc-
tion of LSEC proliferation through influencing multiple pathways. These findings are summarized in Fig. 5.
Discussion
This study demonstrates that hypoxia signaling in HSC leads to a VEGF-driven induction of proliferation of 
LSEC in vitro. Also, in vivo data from the rapid liver regeneration models ALPPS in rats reveal that rapid regen-
eration is associated with an increase in vWF and CD34-positive endothelium in ALPPS compared to PVL and 
activation of HSC as shown by desmin staining and αSMA staining. All of these effects can also be induced by 
treating the animals with DMOG prior to PVL.
supernatants of HSC cultured without (control = blue bar) and incubated with 1 mM dimethyloxalylglycine 
(DMOG = yellow bar) for 24 h, followed by vascular endothelial growth factor (VEGF) depletion (black 
and grey bars, respectively). (G) Liver sinusoidal endothelial cells (LSEC) proliferation measured for 72 h, 
after exposure to control medium (blue) and DMOG-conditioned medium (yellow) from HSC before VEGF 
depletion, and after VEGF depletion (control = black and DMOG = yellow), respectively. A-C, F-G: n = 3 
independent experiments with two measurements for each passage), D-E: n = 4 independent experiments 
with two measurements for each passage were performed for each group. (H) Histological quantification of 
VEGF, in immunohistochemistry staining. Representative regions of interest (ROI) of the right middle lobe 
(RLM), measured 72 h after PVL, ALPPS, PVL+DMOG, DMOG and controls were evaluated. VEGF-positive 
areas were marked red using the threshold function of Image J, counted and expressed as counts per mm2. (I, J) 
Representative photomicrograph of immunohistochemistry with VEGF (red) of rat liver RML 72 h after PVL 
or ALPPS. n = 5 animals for controls and DMOG alone, n = 4 for ALPPS, PVL and PVL+DMOG. 10 ROIs per 
animal were counted. *p < 0.05; **p < 0.01; ***p < 0.001.


















































































































Figure 4. Angiogenesis in rapid liver regeneration models and the activation of hepatic stellate cells in vivo. (A) 
Histological quantification of the endothelial marker von Willebrand factor (vWF) after immunofluorescence 
staining. Regions of interest (ROI) of the right middle lobe (RML) were examined in rat models of PVL, ALPPS, 
PVL+DMOG, DMOG and control. Microvascular cross sections with a diameter below 20 µm were counted 
and related to DAPI-positive nuclei. (B,C) Representative photomicrograph of immunofluorescence staining for 
vWF (red), the proliferation marker Ki67 (green) and DAPI nuclear staining (blue) of rat liver RML 72 h after 
intraperitoneal phosphate-buffered saline (control) or DMOG administration. (D) Histological quantification 
of CD34, which is expressed in endothelial cells only during their differentiation, in immunohistochemistry 
staining. ROI of the right middle lobe (RLM) were evaluated 72 h after PVL, ALPPS, PVL+DMOG, DMOG 
and controls. CD34-positive areas were marked red using the threshold function of Image J, counted and 
expressed as counts per mm2. (E,F) Representative photomicrograph of immunohistochemistry with CD34 of 
rat liver RML 72 h after DMOG administration or control. (G) Histological quantification of desmin, a marker 
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DMOG’s primary known function is to stabilize the HIF𝛼 protein subunits24. Normal livers without por-
tal vein rerouting demonstrate changes in the density of their vascularity by vWF staining after treatment 
with DMOG without proliferation of HC, assuming that the increased vascularity observed after ALPPS and 
PVL+DMOG is probably not secondary to HC proliferation, but an independent process. The cell culture data 
presented here suggest that this process may be initiated by HSC being the DMOG/hypoxia-sensing entity. No 
other pro-proliferative effect of hypoxia-conditioned media of the liver constituents HC, HSC or LSEC on each 
other could be detected in these experiments. Pathway analysis of the RNA expression of the HIF𝛼-stabilized 
HSC and LSEC, stimulated by supernatant from hypoxic HSC, suggests a largely VEGF-dependent angiogenesis, 
metabolic reprogramming and extracellular matrix remodeling (Fig. 5). Vascular endothelial growth factor con-
centration doubled in the supernatant of HIF𝛼-stabilized HSC, and VEGF depletion experiments provided causal 
evidence that the proliferative effect of HSC supernatants on LSEC is mainly dependent on VEGF.
The crosstalk between HSC and LSEC has been investigated mostly in the context of liver fibrosis and cirrho-
sis25, because activation of HSC and angiogenesis are mainly associated with liver fibrosis. Under physiological 
conditions, HSC are known to support the LSEC and their phenotype through the release of VEGF26. While 
VEGF may be constitutively expressed in HSC under normoxic conditions, our cell culture data showed that 
under hypoxic conditions, VEGF production by HSC is increased. We propose that HSC function as hypoxia 
sensors in the liver, and trigger angiogenesis not only in fibrosis and cirrhosis, but also in rapid liver regeneration. 
Interestingly, this effect can be induced by HIF𝛼−stabilizing drugs, while angiogenesis triggered by hypoxia sig-
naling (induced with DMOG) occurs without proliferation of hepatocytes in vivo. Vascular endothelial growth 
factor plays a central role in this signaling cascade, although VEGF depletion from the conditioned medium of 
HSC did not entirely abolish the stimulating effect of DMOG-conditioned HSC media. Other pro-angiogenic 
factors such as endothelin 1 (EDN1)27, and a decrease of anti-angiogenetic factors by HSC could occur and will 
have to be examined in the future.
Slow liver regeneration after PVL and PVE may simply be due to a higher concentration of essential and 
non-essential trophic factors28 for HC besides initial tissue hypoxia. In contrast, proliferation after ALPPS may be 
accelerated, due to the persistently high level of hypoxia in the liver, which induces additional angiogenesis, medi-
ated by activated HSC. The tissue hypoxia in the growing liver is either the result of the arterial buffer response 
due to the portal hyperflow induced in liver rerouting maneuvers and partial hepatectomy29–31 or the result of 
a relative hypermetabolism of the hyperperfused and regenerating liver32. In PVL or PVE, portal hyperflow is a 
short-lived phenomenon of only hours, because it is counteracted by portal vein shunting across sinusoids with 
large collaterals developing over several days11. In ALPPS, hypoxia and thereby HSC activation continues and 
only ceases after the expansion of the sinusoidal capillary bed and the increase in liver size. Any process that 
inhibits collateral formation in portal vein rerouting – like ALPPS and many of its modifications which render 
parenchyma between lobes not viable for collateralization - leads to prolonged and sustained regeneration11 until 
the FLR reaches full liver size, and hypoxic signaling in HSC discontinues. The decrease in hypoxia signaling 
may be a stop-signal of hepatocyte proliferation33 after normalization of portal flow due to expansion of the liver 
sinusoidal endothelial bed to full size. It has been hypothesized that hypoxia has direct pro-proliferative effect on 
HC15,16,34,35, but we now postulate that HC are only effector cells of a process that is initiated and maintained by 
HSC and may be mediated by LSEC proliferation.
The cross talk between LSEC proliferation and HC has to be explored in detail. Angiogenesis may lead, after 
the first three days, to a better vascular perfusion capacity, i.e. the distribution with nutrients and hepatotropic 
substances from the intestine and improve liver function by shorter diffusion of metabolic substance exchange 
and removal36. However, acceleration of HC proliferation in ALPPS and PH is observed already after 24 h13,37 
which may be too early to be explained by angiogenesis. It is more likely that proliferating liver endothelial cells 
and LSEC have an angiocrine role and stimulate HC proliferation through the VEGF pathway and Id1-dependent 
secretion of paracrine trophogens like hepatic growth factor (HGF) and Wnt as previously described36.
A limitation of this study is that there are many endothelial markers for liver endothelial cells and LSEC. We 
picked vWF and CD34 due to the presence of both markers on the immortalized cell cultures we used as screen-
ing tools. A further evaluation of vascular markers development across the liver architecture is needed to under-
stand how endothelial growth accelerates liver regeneration in ALPPS and PLV+DMOG. Second, functional 
proof of the role of HSC for rapid liver regeneration in models of stellate cell depletion or silencing and animals 
genetically deficient for HIF𝛼 and VEGF is still pending and underway.
Prolyl hydroxylase domain-containing enzymes degrade HIF𝛼 subunits and can be blocked by PHI such as 
DMOG38. Prolylhydroxylase inhibitors are interesting novel drugs that simulate hypoxic signaling in all cells of 
the body. The first-in-class PHI Roxadustat met all primary efficacy endpoints in three clinical phase III trials for 
for activated HSC, in immunohistochemistry staining. ROI of the right middle lobe (RLM) were evaluated 
72 h after PVL, ALPPS, PVL+DMOG, DMOG and controls. The desmin-stained area was marked red using 
the threshold function of Image J, measured and expressed as percent of the total area. (H,I) Representative 
photomicrograph of immunohistochemistry with desmin of rat liver RML 72 h after DMOG administration or 
control. (J) Histological quantification of α-smooth-muscle actin (αSMA), a histological marker for stellate cells 
in immunohistochemistry staining. ROI of the right middle lobe (RLM) were evaluated 72 h after PVL, ALPPS, 
PVL+DMOG, DMOG and controls. The area stained for αSMA was marked red using the threshold function 
of Image J, measured and expressed as percent of the total area. (K,L) Representative photomicrograph of 
immunohistochemistry with αSMA of rat liver RML 72 h after DMOG administration or control. n = 5 animals 
for controls and DMOG alone, n = 4 for ALPPS, PVL and PVL+DMOG. 10 ROIs per animal were counted.  
*p < 0.05; ***p < 0.001.
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treatment of renal anemia39. This study suggests they PHI may also be potent inducers of angiogenesis in the liver, 
independently of hepatocyte division. While PHI do not stimulate tumor growth in animals16,24, they may convey 
a cytoprotective effect to hepatocytes as shown by the reduction in apoptosis in this cell culture model. The clini-
cal effects of liver ischemic preconditioning have been attributed to the HIF𝛼 pathway40. Roxadustat has recently 
been approved for human use in China41. In a clinical setting, PHIs could offer accelerated liver regeneration in 
partial hepatectomy, portal vein rerouting and after toxic or ischemic insults.
In conclusion, there is strong cell-culture and in-vivo evidence that hypoxia signaling by HSC with resulting 
angiogenesis plays a role in the acceleration liver regeneration seen in ALPPS and PVL+DMOG. This will have to 
be further evaluated in animals with HSC depletion or lack of hypoxia signaling in HSC.
Methods
Animals, experimental approach and volumetry Approval for the animal experiments with male Wistar rats 
(Charles River, Sulzfeld, Germany) was obtained from the Veterinary Office of the Canton of Zurich, Switzerland 
(number ZH60/2014). Female animals were not considered because of the hormone cycle, which could impact 
on organ regeneration. Experiments were performed in compliance with the guidelines for animal experi-
ments by the Swiss Academy of Medical Sciences and the Federation of European Laboratory Animal Science 
Associations. Food and water were provided ad libitum. Animals were kept at 12/12-hour light/dark cycle in 
ambient temperature of 22 ± 2 °C. A sample size calculation was not performed. The group size is based on 
former experiences, which allows a proper statistical analysis with the least number of animals possible respect-
ing 3 R. Experiments were started (randomization procedure) after seven days of accommodation in ventilated 
cages (n = 5 rats for each group: control, PVL, ALPPS, PVL+DMOG, DMOG alone). Rat models of PVL and 
ALPPS have been established previously37,42–44. The RML was used as the FLR, and PVL as well as ALPPS were 
performed according to previous experiments13,20. For PVL+DMOG, 200 µg/g body weight of the PHI DMOG 
(Frontier Scientific, Newark, DE, USA), was injected intraperitoneally 12 h prior to PVL. In the DMOG group, the 
















Figure 5. Transcriptome analysis of hypoxic stellate cells and liver sinusoidal endothelial cells, exposed to 
the conditioned medium from hypoxic stellate cells. Hepatic stellate cells (HSC) were incubated with 1 mM 
dimethyloxalylglycine (DMOG) for 24 h, supernatants were given as conditioned media to liver sinusoidal 
endothelial cells (LSEC) for 24 h and RNA extracted. Transcriptome analysis, functional annotation of 
differently regulated transcripts using the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID), and evaluation of these genes using the National Center for Biotechnology Information (NCBI) gene 
database revealed a complex, multifunctional induction of angiogenesis and extracellular matrix remodeling 
through DMOG-treated HSC and self-enforcing, pro-proliferative changes in the transcriptome of LSEC 
incubated with conditioned medium of DMOG-treated HSC. Hypoxia-inducible factor (HIF) pathways and 
particularly vascular endothelial growth factor (VEGF) pathway were upregulated. Full transcriptome data sets 
have been uploaded to the NCBI GEO data repository.
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transcutaneously after 24 and 48 h (with PBS as control). Before and 72 h after the respective procedures, animals 
underwent small animal computer tomography (CT) volumetry as previously described13 to assess change of 
volume change of the FLR. The animals were sacrificed at 72 h for tissue procurement.
Immunofluorescence for Ki67, DAPI and vWF. Cryosections of 6 µm were fixed using 4% paraform-
aldehyde (Sigma Aldrich/Merck, Darmstadt, Germany). After 10 min at room temperature, slides were kept in 
ice-cold PBS, washed and blocked at room temperature for 1 h using PBS +2% bovine serum albumin (BSA) 
(KPL, Gaithersburg, MD, USA) + 0.3% Triton X-100 (Sigma Aldrich/Merck). Probes were incubated overnight 
at 4 °C with the following primary antibodies: rabbit anti-Ki67 (Abcam, Cambridge, UK) diluted 1:400, mouse 
anti-vWF (Santa Cruz, Dallas, TX, USA) diluted 1:100 in blocking buffer. After washing, staining was performed 
with secondary antibodies goat anti-mouse Alexa 488 (Life Technologies, Zug, Switzerland), goat anti-rabbit 
Alexa 568 (Abcam), 4,6-diamidin-2-phenylindol (DAPI; Roche, Rotkreuz, Zug, Switzerland) in a 1:1000 dilution 
in PBS for 1 h at room temperature. Slides were mounted with ProLong Gold antifade reagent (Life Technologies).
Images were acquired with either the widefield microscope Leica DMI 6000 B, the fluorescence monochrome 
camera Leica DFC 9000 GTC or the color imaging camera Leica DFC 420 C. Leica Application Suite X 3.0.2.16120 
(Leica Microsystems, Heerbrugg, Switzerland) or the slidescanner Axio Scan.Z1, using ZEN blue image process-
ing and analyzing software (Zeiss, Feldbach, Switzerland). Automated counting of DAPI- and Ki67-positiv nuclei 
was performed with ImageJ 1.51 k (Wayne Rasband, National Institutes of Health, USA), using the watershed tool 
and the Triangle dark auto-threshold for Ki67, an infinity of 2 µm and a circularity of 0.5–1.0. Vascular density 
was assessed in an area of 0.211 mm2 (500 × 1000 Pi) per ROI, excluding artefacts and vessels with a diameter of 
more than 30 µm.
Immunohistochemistry for VEGF, CD34, desmin and αSMA. Formalin fixed tissue was embedded 
in paraffine and sections of 1.5 µm were prepared. The fully automated Leica Bond III stainer (Leica Biosystems, 
Nussloch, Germany) was used to incubate slides in Bond Epitope Retrieval Solution 2 (Biosystems, Muttenz, 
Switzerland) for 20 min at 95 °C and then at room temperature for 15 min with 1:100 diluted rabbit anti-VEGF 
(Abcam, Cambridge, UK), with 1:50 diluted rabbit anti-CD34 (Abcam, Cambridge, UK), with diluted 1:50 mouse 
anti-desmin (CellMarque, Rocklin, CA, USA) or with 1:400 diluted rabbit anti-αSMA (Abcam, Cambridge, 
UK) antibodies. Visualization was achieved using the Leica Bond Polymer Refine Detection technique (Leica 
Biosystems, Nussloch, Germany) according to the manufacturer’s instructions. For VGEF, CD34, and αSMA 
quantification in immunohistochemistry, a 20x objective with aperture was used and the stained area as a fraction 
of a total area of 0.245 mm2 (864 × 648 Pi) was measured with ImageJ 1.51 k.
Cell culture, experimental approach, cell proliferation Hep3B human hepatoma cells, kindly provided by Bruno 
Stieger, University Hospital Zurich, were cultured in DMEM with high glucose (Dulbecco’s Modified Eagle 
Medium; Life Technologies) supplemented with 110 mg/L sodium pyruvate, 10% fetal bovine serum (FBS; Life 
Technologies) and penicillin (100 U/mL)/streptomycin (100 µg/mL) (Life Technologies). LX-2 human hepatic 
stellate cells, kindly provided by Scott Friedman, Mount Sinai School of Medicine, New York, NY, USA, were 
grown as described above, but without pyruvate. TRP3 human liver sinusoidal endothelial cells, kindly pro-
vided by Birke Bartosch, INSERM, Centre de Recherche en Cancérologie de Lyon, France, were cultured in 0.1% 
porcine gelatin-coated plates in MCDB131 medium (Life Technologies) with 10% Fetal Clone II Serum (GE 
Healthcare Lifesciences, South Logan, UT, USA), 10 mmol/l GlutaMAX (Thermo Fischer Scientific, Waltham, 
MA, USA), 1 µg/ml hydrocortisone (Sigma Aldrich/Merck), penicillin/streptomycin as described, 250 µg/ml 
adenosine 3′, 5′-cyclic monophosphate (Sigma Aldrich/Merck) and 50 µg/ml endothelial cell growth supplement 
from bovine tissue (Sigma Aldrich/Merck).
Each cell line was incubated with medium containing 1 mM DMOG (final concentration) for 72 h (according 
control group with medium only) and proliferation was determined. For crosstalk experiments, a specific cell type 
was exposed to DMOG for 24 h. This medium (‘conditioned medium’) was then transferred to another cell line 
and incubated for 72 h (medium from control group).
For hypoxia experiments cells were exposed to 2% oxygen and 5% carbon dioxide in a humified surrounding 
in a regular incubator (INCO 2 153, Memmert, Schwabach, Germany) while control cells were kept at control 
conditions (21% oxygen, 5% carbon dioxide, humified surrounding) in an identical incubator.
Cell proliferation was measured for 72 h using the impedance-based RTCA iCELLigence system (ACEA 
Biosciences, Inc, San Diego, CA, USA). Installation and calibration was carried out according to the manufactur-
er’s instructions. 4500 cells per well, or 2000 cells per well for experiments with conditioned media, were seeded 
into an E-Plate L8. Cells were allowed to adhere for 30 min (HSC, HC) or 120 min (LSEC) before starting the 
measurement. Impedance was measured every 15 min over 72 h. Cell confluency was checked microscopically at 
the end to exclude over-confluent plates. Data were analyzed with the RTCA Data Analysis Software 1.0.
Primary cell culture (pHSC and pLSEC) and experimental setup pLSEC with conditioned 
medium of pHSC. To verify LSEC proliferation in conditioned medium from HSC primary cell culture 
experiments were performed. A human primary liver sinusoidal endothelial cell line as well as a human primary 
liver stellate cell line were purchased from Innoprot, Derio-Bizkaia, Spain (P10652 and P10653, respectively). 6 
well plates were coated with poly-l-lysine (Innoprot) according to the manufacture’s protocol at 37 °C overnight. 
One hundred thousand pHSC were then added to each well in culture medium (Innoprot; medium: stellate 
cell basal medium, fetal bovine serum, stellate cell growth supplement, penicillin/streptomycin solution). After 
reaching 90% confluency pHSC were incubated with PBS as a control and DMOG (1 mM) for 24 h as previously 
described for HSC. After 24 h the supernatants were transferred to pLSEC to quantify proliferation.
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iCELLigence system plates were coated with fibronectin (Innoprot) according to the manufacturers protocol 
for overnight at 37 °C, and pLSEC were seeded at a density of 12000/ml and incubated with the collected super-
natants of the pHSC.
VEGF ELISA, VEGF depletion experiments Vascular endothelial growth factor was measured using 
enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s instructions (R&D Systems, 
Abingdon, UK). For VEGF depletion, 24-well plates were coated overnight with a capture antibody from the 
ELISA kit in a 1:120 dilution in PBS, followed by two washing steps. 150 µl conditioned medium of DMOG-treated 
or untreated HSC was added to the VEGF antibody-coated well for 1 h at room temperature under constant 
movement. This step was repeated once. Subsequently, LSEC were then incubated with the VEGF-depleted con-
ditioned medium from HSC, and proliferation was measured for 72 h, as described.
Transcriptome and GeneChip microarray assay Total RNA was extracted from cultured LX-2 and TRP3 accord-
ing to the manufacturer’s instructions using the RNeasy Mini Kit (Qiagen, Hilden, Germany) after 24 h of incuba-
tion with DMOG or supernatants of DMOG-treated HSC. Sample preparation for microarray hybridization was 
performed using the Affymetrix GeneChip WT PLUS Reagent Kit according to the Manifacturers Instructions 
(Affymetrix, Inc., Santa Clara, CA, USA). Sample processing was performed at an Affymetrix Service Provider 
and Core Facility, “KFB - Center of Excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.
kfb-regensburg.de). Summarized probe set signals in log2 scale were calculated by using the GCCN-SST-RMA 
algorithm with the Affymetrix GeneChip Expression Console v1.4 Software. After exporting into Microsoft Excel, 
average signal values, comparison fold changes and significance P values were calculated. Probes with an at least 
2-fold change and a p value lower than 0.01 were considered significantly regulated. Functional annotation of 
differently regulated transcripts was performed using the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID)21,22 and genes referred to in the clusters ‘HIF-1 pathway’, ‘VEGF pathway’, ‘angiogenesis’, 
‘apoptosis’, ‘p53 pathway’, ‘extracellular matrix (ECM)-ECM-receptor-interaction’ were further evaluated using 
the National Center for Biotechnology Information gene database (NCBI, U.S. National Library of Medicine, 
Bethesda, MD, USA).
Statistical analysis Unpaired Student t test (GraphPad, San Diego, CA, USA) was used to compare the animal 
models after confirming normal distribution with the Kolmogorov-Smirnov test. Due to the large number of 
cells assessed in the cell proliferation assays, the in vitro studies consisted of a minimum of three independent 
experiments (passages of cells from a frozen state) performed in duplicate measurements. The exact number of 
passages used for each experiment is given in the results section. For statistical evaluation of cell growth, a linear 
regression including a bias corrected and accelerated bootstrapping with 1000 random samples and a confidence 
interval of 95% was performed. Requirements were controlled by a residual analysis. Unpaired Student t test was 
used to compare the ELISA values between groups.
Data availability
Data repository for transcriptome data NCBI’s GEO, URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.
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